Related Experiment Videos
Caffeine and cerebral blood flow velocity in preterm infants
Insights
Caffeine citrate loading doses did not alter cerebral blood flow velocity (CBFV) in preterm neonates with apnea. Heart rate and respiratory rate increased, but blood pressure and gas exchange remained stable.
Area of Science:
- Neonatal Physiology
- Pharmacology
- Cerebrovascular Regulation
Background:
- Apnea of prematurity is a common condition in preterm neonates.
- Caffeine citrate is a standard treatment for apnea of prematurity.
- The effect of caffeine on cerebral blood flow velocity (CBFV) in neonates requires further investigation.
Purpose of the Study:
- To evaluate the impact of a caffeine citrate loading dose on CBFV in preterm neonates with apnea.
- To assess associated changes in cardiorespiratory parameters and blood gases.
Main Methods:
- A randomized, placebo-controlled, crossover study was conducted in 7 clinically stable preterm neonates.
- Continuous wave Doppler was used to measure CBFV.
- Heart rate, arterial blood pressure, respiratory rate, TcPO2, and TcCO2 were monitored simultaneously.
Main Results:
- Caffeine citrate administration did not result in significant changes in CBFV compared to placebo.
- A statistically significant increase in heart rate and respiratory rate was observed post-caffeine.
- Mean arterial blood pressure, TcPO2, and TcCO2 showed no significant alterations.
Conclusions:
- The standard 20 mg.kg-1 BW loading dose of caffeine citrate does not affect CBFV in preterm neonates with apnea.
- Caffeine citrate appears safe regarding cerebral hemodynamics and gas exchange at this dosage.
- Further research may explore the effects of different caffeine dosages or chronic administration on neonatal CBFV.
Abstract:
Continuous wave Doppler monitor was used to examine the effect on cerebral blood flow velocity (CBFV) of caffeine in 7 clinically stable preterm neonates suffering from apnea. Caffeine, as caffeine citrate at a loading dose of 20 mg.kg-1 BW, or saline were given intravenously. Every subject was his own control. Placebo (saline) was systematically injected prior to caffeine citrate. Simultaneous recording of heart rate, arterial blood pressure, respiratory rate, Tc PO2, and Tc PCO2 were made before, at the end of the injection, and 30, 60 and 120 min after the end of each administration of either placebo or caffeine. Compared with placebo, caffeine injection was not associated with significant changes in CBFV. An increase was found in both heart rate and respiratory rate (p less than 0.05). Mean arterial blood pressure, Tc PCO2 and Tc PO2 did not change significantly. Our data suggest that a caffeine citrate loading dose of 20 mg.kg-1 BW as currently used at the beginning of treatment of apnea in preterm neonates has no effect on CBFV.